Published: March 6, 2019 | Updated: March 10, 2023
Atrial fibrillation (A-fib) is the most common cardiac arrhythmia, currently affecting over 5 million people in the U.S. Twenty percent of all strokes occur in patients with A-fib; and A-fib-related strokes are more frequently fatal and disabling. The most common treatment to reduce stroke risk in patients with A-fib is a blood-thinning medication such as warfarin.
However, long-term warfarin use is not well-tolerated by some patients and has increased risks for excessive bleeding, falls, inadequate blood-thinning and an overall risk of being on medication for an extended period of time.
Learn more about A-fib and advanced treatment options. Register Now
(502) 891-8400
Because of these issues, nearly 50 percent of A-fib patients eligible for warfarin are untreated.
The implant closes off an area of the heart called the left atrial appendage to keep harmful clots from entering the bloodstream and potentially causing a stroke.
The procedure is performed under general anesthesia in a cardiac electrophysiology lab, using a standard percutaneous (through the skin) technique in which a guidewire and vessel dilator are inserted into the femoral vein. The one-time procedure takes about an hour to complete, and patients typically remain in the hospital for 24 hours.
You may be right for an implant if you meet the following criteria:
Select an appointment date and time from available spots listed below.